Concepedia

Marie C. Fanget

MC

Statistics

Publications

4

Citations

65

H-Index

4

Active since

2021

Affiliations

VIR Biotechnology (United States)(Current)

Vir Biotechnology (Switzerland)

Marie C. Fanget is an author at VIR Biotechnology (United States) specializing in viral hepatitis treatment, pharmacokinetics, and antiviral therapy.

Publications per year

2021–2024

4

Publications

4

Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection

Sneha Gupta, Marie C. Fanget, Christopher MacLauchlin et al. · Drugs in R&D · 2021 · 28 citations · Full text

, , +17

In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys

Tolulope A. Aweda, Shih‐Hsun Cheng, Stephen C. Lenhard et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2022 · 14 citations · Full text

, , +17

Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody

Kosh Agarwal, Man‐Fung Yuen, Heiner Wedemeyer et al. · Journal of Hepatology · 2022 · 12 citations

, , +14

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness

David Plotnik, Jennifer E. Sager, Madhukar Aryal et al. · Antimicrobial Agents and Chemotherapy · 2024 · 11 citations · Full text

, , +14

1–4 of 4